GlassScriptPhysician profile
Barbara A Gilman
NPI 1386830958
$3,673.41
in general payments reported to CMS, 2019-2025
14 companies · $1,671 in 2025
The $1,671 reported for 2025 was more than what 94% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $243 · 2022: $615 · 2023: $284 · 2024: $860 · 2025: $1,671.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,815.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,814.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,085.12 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $586.44 | 2025 | Airsupra, Breztri |
| Novo Nordisk INC | $439.55 | 2021-2025 | Ozempic |
| Amgen INC. | $355.71 | 2023-2025 | Repatha |
| Phathom Pharmaceuticals, INC. | $306.33 | 2024-2025 | Voquezna |
| Axsome Therapeutics, INC. | $208.91 | 2025 | Auvelity, Symbravo |
| Ironwood Pharmaceuticals, INC | $142.84 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.00 | 2022 | |
| Abbvie INC. | $124.99 | 2022 | |
| Pfizer INC. | $113.98 | 2025 | |
| Biohaven Pharmaceuticals, INC. | $103.55 | 2021 | |
| Exact Sciences Corporation | $39.03 | 2024 | Cologuard Collection Kit |
| Hologic Sales and Service, LLC | $21.34 | 2025 | Aptima, Thinprep 2000 Processor |
| Dexcom, INC. | $20.62 | 2025 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Gilman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.